Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial

Trial Profile

Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 17 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top